News articles about Heska (NASDAQ:HSKA) have been trending positive on Friday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heska earned a coverage optimism score of 0.27 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 45.2591761011112 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Heska (NASDAQ:HSKA) traded down $1.04 during trading hours on Friday, reaching $59.96. The company had a trading volume of 59,700 shares, compared to its average volume of 93,145. Heska has a 52-week low of $56.59 and a 52-week high of $115.00. The firm has a market capitalization of $441.87, a price-to-earnings ratio of 31.94, a price-to-earnings-growth ratio of 1.58 and a beta of 0.67.
Several equities research analysts have issued reports on the company. Sidoti upgraded Heska from a “neutral” rating to a “buy” rating and set a $94.00 price target for the company in a report on Monday, February 5th. Aegis restated a “buy” rating on shares of Heska in a research note on Tuesday, December 19th. Raymond James Financial restated a “buy” rating on shares of Heska in a research note on Monday, December 4th. BidaskClub upgraded Heska from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Finally, B. Riley reiterated a “hold” rating and set a $96.50 price target on shares of Heska in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $110.08.
In other news, insider Michael J. Mcginley sold 7,826 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total transaction of $681,957.64. Following the completion of the sale, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 14.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/23/positive-news-coverage-somewhat-unlikely-to-affect-heska-hska-stock-price.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.